Literature DB >> 25217527

MicroRNA100 inhibits self-renewal of breast cancer stem-like cells and breast tumor development.

Lu Deng1, Li Shang2, Shoumin Bai3, Ji Chen1, Xueyan He1, Rachel Martin-Trevino2, Shanshan Chen3, Xiao-Yan Li4, Xiaojie Meng5, Bin Yu1, Xiaolin Wang1, Yajing Liu2, Sean P McDermott2, Alexa E Ariazi2, Christophe Ginestier6, Ingrid Ibarra7, Jia Ke8, Tahra Luther2, Shawn G Clouthier2, Liang Xu5, Ge Shan1, Erwei Song9, Herui Yao3, Gregory J Hannon7, Stephen J Weiss4, Max S Wicha2, Suling Liu10.   

Abstract

miRNAs are essential for self-renewal and differentiation of normal and malignant stem cells by regulating the expression of key stem cell regulatory genes. Here, we report evidence implicating the miR100 in self-renewal of cancer stem-like cells (CSC). We found that miR100 expression levels relate to the cellular differentiation state, with lowest expression in cells displaying stem cell markers. Utilizing a tetracycline-inducible lentivirus to elevate expression of miR100 in human cells, we found that increasing miR100 levels decreased the production of breast CSCs. This effect was correlated with an inhibition of cancer cell proliferation in vitro and in mouse tumor xenografts due to attenuated expression of the CSC regulatory genes SMARCA5, SMARCD1, and BMPR2. Furthermore, miR100 induction in breast CSCs immediately upon their orthotopic implantation or intracardiac injection completely blocked tumor growth and metastasis formation. Clinically, we observed a significant association between miR100 expression in breast cancer specimens and patient survival. Our results suggest that miR100 is required to direct CSC self-renewal and differentiation. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25217527      PMCID: PMC4370193          DOI: 10.1158/0008-5472.CAN-13-3710

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

1.  miRNA 34a, 100, and 137 modulate differentiation of mouse embryonic stem cells.

Authors:  Carolina Tarantino; Gaetana Paolella; Luca Cozzuto; Giuseppina Minopoli; Lucio Pastore; Silvia Parisi; Tommaso Russo
Journal:  FASEB J       Date:  2010-05-03       Impact factor: 5.191

Review 2.  Targeting breast cancer stem cells.

Authors:  Suling Liu; Max S Wicha
Journal:  J Clin Oncol       Date:  2010-05-24       Impact factor: 44.544

3.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.

Authors:  T Sørlie; C M Perou; R Tibshirani; T Aas; S Geisler; H Johnsen; T Hastie; M B Eisen; M van de Rijn; S S Jeffrey; T Thorsen; H Quist; J C Matese; P O Brown; D Botstein; P E Lønning; A L Børresen-Dale
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

4.  Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells.

Authors:  Dimitrios Iliopoulos; Marianne Lindahl-Allen; Christos Polytarchou; Heather A Hirsch; Philip N Tsichlis; Kevin Struhl
Journal:  Mol Cell       Date:  2010-09-10       Impact factor: 17.970

Review 5.  Tumor-targeted p53-gene therapy enhances the efficacy of conventional chemo/radiotherapy.

Authors:  L Xu; K F Pirollo; E H Chang
Journal:  J Control Release       Date:  2001-07-06       Impact factor: 9.776

6.  miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation.

Authors:  Dandan Sun; Yong Sun Lee; Ankit Malhotra; Hak Kyun Kim; Mirela Matecic; Clive Evans; Roderick V Jensen; Christopher A Moskaluk; Anindya Dutta
Journal:  Cancer Res       Date:  2011-01-06       Impact factor: 12.701

7.  An integrated transcriptional regulatory circuit that reinforces the breast cancer stem cell state.

Authors:  Christos Polytarchou; Dimitrios Iliopoulos; Kevin Struhl
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-20       Impact factor: 11.205

8.  miR-100 suppresses IGF2 and inhibits breast tumorigenesis by interfering with proliferation and survival signaling.

Authors:  C A Gebeshuber; J Martinez
Journal:  Oncogene       Date:  2012-08-27       Impact factor: 9.867

9.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.

Authors:  Christina Curtis; Sohrab P Shah; Suet-Feung Chin; Gulisa Turashvili; Oscar M Rueda; Mark J Dunning; Doug Speed; Andy G Lynch; Shamith Samarajiwa; Yinyin Yuan; Stefan Gräf; Gavin Ha; Gholamreza Haffari; Ali Bashashati; Roslin Russell; Steven McKinney; Anita Langerød; Andrew Green; Elena Provenzano; Gordon Wishart; Sarah Pinder; Peter Watson; Florian Markowetz; Leigh Murphy; Ian Ellis; Arnie Purushotham; Anne-Lise Børresen-Dale; James D Brenton; Simon Tavaré; Carlos Caldas; Samuel Aparicio
Journal:  Nature       Date:  2012-04-18       Impact factor: 49.962

10.  miR-100 induces epithelial-mesenchymal transition but suppresses tumorigenesis, migration and invasion.

Authors:  Dahu Chen; Yutong Sun; Yuan Yuan; Zhenbo Han; Peijing Zhang; Jinsong Zhang; M James You; Julie Teruya-Feldstein; Min Wang; Sumeet Gupta; Mien-Chie Hung; Han Liang; Li Ma
Journal:  PLoS Genet       Date:  2014-02-27       Impact factor: 5.917

View more
  32 in total

Review 1.  Potential role of miR-100 in cancer diagnosis, prognosis, and therapy.

Authors:  Chu Qin; Ru-Yi Huang; Zhao-Xia Wang
Journal:  Tumour Biol       Date:  2015-03-05

2.  Probing the interaction between the histone methyltransferase/deacetylase subunit RBBP4/7 and the transcription factor BCL11A in epigenetic complexes.

Authors:  Rebecca Reed Moody; Miao-Chia Lo; Jennifer L Meagher; Chang-Ching Lin; Nicholas O Stevers; Samantha L Tinsley; Inkyung Jung; Aleksas Matvekas; Jeanne A Stuckey; Duxin Sun
Journal:  J Biol Chem       Date:  2017-12-20       Impact factor: 5.157

3.  MicroRNA-100 shuttled by mesenchymal stem cell-derived exosomes suppresses in vitro angiogenesis through modulating the mTOR/HIF-1α/VEGF signaling axis in breast cancer cells.

Authors:  Katayoon Pakravan; Sadegh Babashah; Majid Sadeghizadeh; Seyed Javad Mowla; Majid Mossahebi-Mohammadi; Farangis Ataei; Nasim Dana; Mohammad Javan
Journal:  Cell Oncol (Dordr)       Date:  2017-07-24       Impact factor: 6.730

Review 4.  Research progress in breast cancer stem cells: characterization and future perspectives.

Authors:  Xiao-Dong Mao; Xiao Wei; Tao Xu; Tai-Ping Li; Kang-Sheng Liu
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

Review 5.  Non-coding RNAs: the new central dogma of cancer biology.

Authors:  Phei Er Saw; Xiaoding Xu; Jianing Chen; Er-Wei Song
Journal:  Sci China Life Sci       Date:  2020-09-11       Impact factor: 6.038

6.  MiR-1228 promotes breast cancer cell growth and metastasis through targeting SCAI protein.

Authors:  Luoqiang Lin; Dan Liu; Hongyan Liang; Li Xue; Changlei Su; Ming Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

7.  BMPR2-pSMAD1/5 signaling pathway regulates RUNX2 expression and impacts the progression of dedifferentiated chondrosarcoma.

Authors:  Kang Yang; Xiao-Dong Tang; Wei Guo; Xiao-Long Xu; Ting-Ting Ren; Cong-Min Ren; Shi-Dong Wang; Xing Bao; Fan Zhang; Kun-Kun Sun
Journal:  Am J Cancer Res       Date:  2016-06-01       Impact factor: 6.166

8.  Integration of microRNA signatures of distinct mammary epithelial cell types with their gene expression and epigenetic portraits.

Authors:  Bhupinder Pal; Yunshun Chen; Andrew Bert; Yifang Hu; Julie M Sheridan; Tamara Beck; Wei Shi; Keith Satterley; Paul Jamieson; Gregory J Goodall; Geoffrey J Lindeman; Gordon K Smyth; Jane E Visvader
Journal:  Breast Cancer Res       Date:  2015-06-18       Impact factor: 6.466

9.  The role of miR-100 in regulating apoptosis of breast cancer cells.

Authors:  Yi Gong; Tianliang He; Lu Yang; Geng Yang; Yulei Chen; Xiaobo Zhang
Journal:  Sci Rep       Date:  2015-07-01       Impact factor: 4.379

10.  By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy.

Authors:  Annalisa Petrelli; Rosachiara Carollo; Marilisa Cargnelutti; Flora Iovino; Maurizio Callari; Daniela Cimino; Matilde Todaro; Laura Rosa Mangiapane; Alessandro Giammona; Adriana Cordova; Filippo Montemurro; Daniela Taverna; Maria Grazia Daidone; Giorgio Stassi; Silvia Giordano
Journal:  Oncotarget       Date:  2015-02-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.